WO1985004324A1 - Bioprosthetic conduits - Google Patents
Bioprosthetic conduits Download PDFInfo
- Publication number
- WO1985004324A1 WO1985004324A1 PCT/GB1985/000129 GB8500129W WO8504324A1 WO 1985004324 A1 WO1985004324 A1 WO 1985004324A1 GB 8500129 W GB8500129 W GB 8500129W WO 8504324 A1 WO8504324 A1 WO 8504324A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ureter
- bioprosthetic
- conduit
- internal surface
- ureters
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/062—Apparatus for the production of blood vessels made from natural tissue or with layers of living cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
Definitions
- the present invention relates to bioprosthetic conduits comprising animal ureters, and in particular to such conduits when employed as replacement blood vessels, and to methods of preparing such conduits.
- Human umbilical arteries and veins have also been used as well as non-human animal arteries and veins from, for example, sheep and cows. Also, wholly artificial conduits comprising knitted synthetic fibre fabrics or cast plastics materials have been employed.
- the present invention provides a bioprosthetic conduit comprising an animal ureter which has been subjected to a fixation treatment while in a distended condition sufficient to expand the ureter to give a substantially smooth internal surface thereto.
- platelet aggregation, fibrin deposition and neointimal hyperplasia may be advantageously influenced by prior treatment of the bioprosthetic conduit with glycerol.
- ureters taken from pigs are employed, but ureters from other animals, such as sheep and calves, may also be mentioned.
- Pig ureters can provide a 25-30 cm conduit length free from collaterals, with an average internal diameter of 2-6 mm and a corresponding outside diameter of 3-7 mm.
- the invention also provides a method of preparing a bioprosthetic conduit comprising an animal ureter in which the ureter is subjected to a fixation treatment while in a distended condition sufficient to expand the ureter to give a substantially smooth internal surface thereto.
- the fixation treatment employed is based on the use of gluteraldehyde solution.
- An essential feature of the present invention is the application of the fixation treatment while the ureter is in a distended, open condition. In the relaxed condition the ureter is closed and the internal surface thereof highly convoluted. Before the fixation treatment the ureter must be distended so as to expand its internal surface to substantially remove the convolutions to give a substantially smooth surface.
- Freshly removed pig ureters are stripped of exterior fat and thoroughly washed through with isotonic saline (0.9 % sodium chloride) at 4 °C. Each ureter is then mounted and secured on a bell-ended cannular, flushed through with glycerol and left immersed in glycerol for 7 days. The glycerol is washed from the ureter by an isotonic phosphate buffer solution of pH 7.4. The distal ends of the ureters are then secured and a pressure of 50 mm mercury is applied to the buffer solution to distend the ureters. Alternatively, the ureters may be cannulated at both ends and buffer solution passed therethrough under a pressure of 50 mm mercury to distend the ureters.
- the ureters are held in a straight position. Under a pressure of 50 mm mercury the ureter wall is expanded and the ureter opened to provide a continuous hole therethrough. Such expansion has the effect of substantially removing the internal surface convolutions of the ureter to provide a substantially smooth internal surface.
- the distended ureters are then totally immersed vertically in a bath of the phosphate buffer solution using small weights to maintain the ureters in the vertical position.
- An overflow from the buffer reservoir to the bath ensures the circulation of the buffer solution .
- the bath is then charged with sufficient 25 % gluteraldehyde solution to achieve a final concentration in the bath of 0.2 %, and the distended ureters are allowed to fix therein for at least 18 hours, during which time the gluteraldehyde solution is under circulation.
- the distended ureters with substantially smooth internal surfaces are sterilised by placing in a 4 % formaldehyde solution for 24 hours.
Abstract
A bioprosthetic conduit comprising an animal ureter, for example, the ureter from a pig, which is employed as a remplacement blood vessel, for example, as a replacement for a human coronary artery. The ureter is subjected to a fixation treatment while in a distended condition sufficient to remove the convoluted internal surface thereof to give a substantially smooth internal surface.
Description
BIOPROSTHETIC CONDUITS
The present invention relates to bioprosthetic conduits comprising animal ureters, and in particular to such conduits when employed as replacement blood vessels, and to methods of preparing such conduits.
Inefficient human arteries, especially coronary arteries, are commonly replaced/bypassed with other arteries or veins taken from the patient, typically the carotid artery or saphenous vein, or with arteries or veins from other human donors or human post mortem material. Human umbilical arteries and veins have also been used as well as non-human animal arteries and veins from, for example, sheep and cows. Also, wholly artificial conduits comprising knitted synthetic fibre fabrics or cast plastics materials have been employed.
So far, none of these "substitute" arteries has proved particularly satisfactory for one or more of a variety of reasons, but essentially because of the presence along the length of the replacement conduit of collateral or branch conduits which require sealing in natural substitutes, and the unacceptable build up of neointimal hyperplasia that is liable in the case of wholly artifical conduits.
Thus, since the advent of coronary artery replacement surgery in the late 1960's, the object and practice has traditionally been to replace existing blood vessels with other blood vessels, with the exception in recent years of the limited use of some wholly artifical conduits; and because of the known disadvantages referred to above, considerable, but so far unsuccessful efforts, have been expended in trying to minimise and/or avoid these problems. In the present invention, the disadvantages
described above with respect to existing substitute arteries have been effectively and unexpectedly overcome, by a totally different approach to the selection of suitable replacement conduit material. Thus, the present invention provides a bioprosthetic conduit comprising an animal ureter which has been subjected to a fixation treatment while in a distended condition sufficient to expand the ureter to give a substantially smooth internal surface thereto.
The Applicants have also found that platelet aggregation, fibrin deposition and neointimal hyperplasia may be advantageously influenced by prior treatment of the bioprosthetic conduit with glycerol.
Preferably, ureters taken from pigs are employed, but ureters from other animals, such as sheep and calves, may also be mentioned. Pig ureters can provide a 25-30 cm conduit length free from collaterals, with an average internal diameter of 2-6 mm and a corresponding outside diameter of 3-7 mm.
The invention also provides a method of preparing a bioprosthetic conduit comprising an animal ureter in which the ureter is subjected to a fixation treatment while in a distended condition sufficient to expand the ureter to give a substantially smooth internal surface thereto.
Preferably, the fixation treatment employed is based on the use of gluteraldehyde solution. An essential feature of the present invention is the application of the fixation treatment while the ureter is in a distended, open condition. In the relaxed condition the ureter is closed and the internal surface thereof highly convoluted. Before the fixation treatment the ureter
must be distended so as to expand its internal surface to substantially remove the convolutions to give a substantially smooth surface.
The following example of the present invention is not to be construed as limiting the invention.
Freshly removed pig ureters are stripped of exterior fat and thoroughly washed through with isotonic saline (0.9 % sodium chloride) at 4 °C. Each ureter is then mounted and secured on a bell-ended cannular, flushed through with glycerol and left immersed in glycerol for 7 days. The glycerol is washed from the ureter by an isotonic phosphate buffer solution of pH 7.4. The distal ends of the ureters are then secured and a pressure of 50 mm mercury is applied to the buffer solution to distend the ureters. Alternatively, the ureters may be cannulated at both ends and buffer solution passed therethrough under a pressure of 50 mm mercury to distend the ureters. In both cases the ureters are held in a straight position. Under a pressure of 50 mm mercury the ureter wall is expanded and the ureter opened to provide a continuous hole therethrough. Such expansion has the effect of substantially removing the internal surface convolutions of the ureter to provide a substantially smooth internal surface.
The distended ureters are then totally immersed vertically in a bath of the phosphate buffer solution using small weights to maintain the ureters in the vertical position. An overflow from the buffer reservoir to the bath ensures the circulation of the buffer solution .
The bath is then charged with sufficient 25 % gluteraldehyde solution to achieve a final
concentration in the bath of 0.2 %, and the distended ureters are allowed to fix therein for at least 18 hours, during which time the gluteraldehyde solution is under circulation. After fixing, the distended ureters with substantially smooth internal surfaces, are sterilised by placing in a 4 % formaldehyde solution for 24 hours.
Hydrodynamic tests have established that the fixed ureters according to the present invention will withstand a pressure of 1500 mm mercury - well above the pressure normally experienced in human arteries (approximately 150 mm Hg).
Experimental implantation in dogs has proved successful, demonstrating no immediate thrombus formation, or restriction of the blood flow due to the innate condition of the bioprosthetic conduit.
Claims
1. A bioprosthetic conduit comprising an animal ureter which has been subjected to a fixation treatment while in a distended condition sufficient to expand the ureter to give a substantially smooth internal surface thereto.
2. A conduit as claimed in claim 1 c omprising a non-human ureter.
3. A conduit as claimed in claim 2 comprising a pig ureter.
4. A method of preparing a bioprosthetic conduit comprising an animal ureter in which the ureter is subjected to fixation treatment while in a distended condition sufficient to expand the ureter to give a substantially smooth internal surface thereto.
5. A method as claimed in claim 4 in which a non-human ureter is used.
6. A method as claimed in claim 5 in which a pig ureter is used.
7. A method as claimed in any one of claims 4 to 6 in which the ureter is pre -treated with glycerol.
8. A method as claimed in any one of claims 4 to 7 in which the ureter is treated with a glutαraldehyde solution.
9. A bioprosthetic conduit substantially as hereinbefore described with reference to the example of the invention.
10. A method of preparing a bioprosthetic conduit substantially as hereinbefore described with reference to the example of the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8408384 | 1984-03-31 | ||
GB08408384A GB2156677A (en) | 1984-03-31 | 1984-03-31 | Bioprosthetic conduits |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1985004324A1 true WO1985004324A1 (en) | 1985-10-10 |
Family
ID=10559008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1985/000129 WO1985004324A1 (en) | 1984-03-31 | 1985-03-29 | Bioprosthetic conduits |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0175740A1 (en) |
AU (1) | AU4154185A (en) |
GB (1) | GB2156677A (en) |
WO (1) | WO1985004324A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2180755A (en) * | 1985-09-26 | 1987-04-08 | Wessex Medical Group Ltd | Methods for preparing bioprosthetic conduits |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1018288A (en) * | 1963-06-15 | 1966-01-26 | Spofa Vereinigte Pharma Werke | Artificial blood vessels and method of preparing the same |
GB1510163A (en) * | 1975-07-08 | 1978-05-10 | Hancock Laboratories Inc | Preparing natural tissue for implantation |
WO1982000091A1 (en) * | 1980-07-01 | 1982-01-21 | V Ketharanathan | Vascular prostheses |
US4357274A (en) * | 1981-08-06 | 1982-11-02 | Intermedicat Gmbh | Process for the manufacture of sclero protein transplants with increased biological stability |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974526A (en) * | 1973-07-06 | 1976-08-17 | Dardik Irving I | Vascular prostheses and process for producing the same |
US3988782A (en) * | 1973-07-06 | 1976-11-02 | Dardik Irving I | Non-antigenic, non-thrombogenic infection-resistant grafts from umbilical cord vessels and process for preparing and using same |
GB2075819A (en) * | 1980-05-15 | 1981-11-25 | Wee Julian Teow Keong | Biosynthetic micrografts from chorionic vessels and process for preparing same |
-
1984
- 1984-03-31 GB GB08408384A patent/GB2156677A/en not_active Withdrawn
-
1985
- 1985-03-29 WO PCT/GB1985/000129 patent/WO1985004324A1/en unknown
- 1985-03-29 EP EP85901504A patent/EP0175740A1/en not_active Withdrawn
- 1985-03-29 AU AU41541/85A patent/AU4154185A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1018288A (en) * | 1963-06-15 | 1966-01-26 | Spofa Vereinigte Pharma Werke | Artificial blood vessels and method of preparing the same |
GB1510163A (en) * | 1975-07-08 | 1978-05-10 | Hancock Laboratories Inc | Preparing natural tissue for implantation |
WO1982000091A1 (en) * | 1980-07-01 | 1982-01-21 | V Ketharanathan | Vascular prostheses |
US4357274A (en) * | 1981-08-06 | 1982-11-02 | Intermedicat Gmbh | Process for the manufacture of sclero protein transplants with increased biological stability |
Also Published As
Publication number | Publication date |
---|---|
GB2156677A (en) | 1985-10-16 |
AU4154185A (en) | 1985-11-01 |
EP0175740A1 (en) | 1986-04-02 |
GB8408384D0 (en) | 1984-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4704131A (en) | Medical materials | |
US4083066A (en) | Heterologous arterial transplants | |
US3974526A (en) | Vascular prostheses and process for producing the same | |
CA1247007A (en) | Treatment of collagenous tissue | |
US4801299A (en) | Body implants of extracellular matrix and means and methods of making and using such implants | |
US4466139A (en) | Vascular prostheses | |
JPH10507102A (en) | Method for treating implantable biological tissue to reduce calcification and bioprostheses treated in such a manner | |
ROSENBERG et al. | The use of arterial implants prepared by enzymatic modification of arterial heterografts: II. The physical properties of the elastica and collagen components of the arterial wall | |
Senatore et al. | Clinical study of urokinase‐bound fibrocollagenous tubes | |
US4240794A (en) | Method of preforming vascular grafts of human and other animal origin | |
Ketharnathan et al. | Glutaraldehyde-tanned ovine collagen conduits as vascular xenografts in dogs: a preliminary report | |
US4695281A (en) | Medical material | |
WO1985004324A1 (en) | Bioprosthetic conduits | |
EP1123122B1 (en) | Implant material | |
GB2180755A (en) | Methods for preparing bioprosthetic conduits | |
CA2342947A1 (en) | Artificial blood vessel | |
JPH04288165A (en) | Organ implant and manufacture thereof | |
Trudell et al. | Alcohol-treated PTFE vascular grafts | |
Kiraly et al. | Natural tissue as a biomaterial | |
EP0124659A1 (en) | Medical material | |
Wallin et al. | Screening and evaluation of materials for thromboresistance | |
Pessana et al. | Adaptive Filtering of the Arterial Wall: Frequency Response and Dynamical Parameters: Clinical Evaluation | |
Noishiki | Fibrocollagenous tissue tube as a small arterial substitute | |
Macewen | Clinical lectures on some points connected with the treatment of wounds | |
JP2001137329A (en) | Bio-tissue for tendon or ligament and method of manufacturing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU JP US |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR IT LU NL |